



July 27, 2015

EnteroMedics Announces the Launch of vBloc® Access

Program Designed to Support Patient Access to vBloc Neurometabolic Therapy

ST. PAUL, Minn., July 27, 2015 /PRNewswire/ -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking therapy to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the launch of vBloc® Access, a program designed to support patient access to vBloc Neurometabolic Therapy.

vBloc Access is a comprehensive patient support program that provides individuals considering vBloc Neurometabolic Therapy with help in understanding their insurance benefits and the insurance claim process. vBloc Access is available to physicians and healthcare providers as a resource for navigating the reimbursement process, including billing and coding assistance.

Case management experts are available to patients online at www.vbloc.com, and through a reimbursement support hotline at 1-866-77VBLOC (866-778-2562).

"EnteroMedics is pleased to offer patients and physicians with a resource to help them navigate the reimbursement process and provide expanded access to vBloc Neurometabolic Therapy," said Brad Hancock, EnteroMedics Chief Commercial Officer. "vBloc Neurometabolic Therapy is a unique product that enables healthy weight loss through a better patient experience. With the vBloc Access program, we look forward to supporting physicians and patients in meeting the rapidly growing interest in and demand for vBloc Neurometabolic Therapy."

About EnteroMedics Inc.

EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. EnteroMedics' Maestro Rechargeable System has received U.S. Food and Drug Administration approval, CE Mark and is listed on the Australian Register of Therapeutic Goods.

Information about the Maestro® Rechargeable System and vBloc® Therapy

You should not have an implanted Maestro Rechargeable System if you have cirrhosis of the liver, high blood pressure in the veins of the liver, enlarged veins in your esophagus or a significant hiatal hernia of the stomach; if you need magnetic resonance imaging (MRI); if you have a permanently implanted, electrical medical device; or if you need a diathermy procedure using heat. The most common related adverse events that were experienced during clinical study of the Maestro System included pain, heartburn, nausea, difficulty swallowing, belching, wound redness or irritation, and constipation.

Talk with your doctor about the full risks and benefits of vBloc® Neurometabolic Therapy and the Maestro Rechargeable System. For additional prescribing information, please visit www.enteromedics.com

If you are interested in learning more about vBloc Neurometabolic Therapy, please visit www.enteromedics.com/vbloc or call 1-800-MY-VBLOC.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial sales experience with our Maestro® Rechargeable System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and vBloc® Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other

personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 13, 2015. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/enteromedics-announces-the-launch-of-vbloc-access-300118768.html>

SOURCE EnteroMedics Inc.

News Provided by Acquire Media